
    
      B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group
      design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100
      psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with
      schizophrenia are on background treatment with SOC antipsychotics and other psychotropic
      medications.

      All doses will be administered twice daily, with approximately 12 hours between each dose.
    
  